Table 5.
Associations of Ang2 rs12674822 genotypic frequencies with laboratory status in the NSCLC cohort.
| Variable | GG N=182 (%) |
GT N=345 (%) |
OR (95% CI) | AOR (95% CI) |
|---|---|---|---|---|
| Clinical Stage | ||||
| Stage I | 145 (79.7) | 247 (71.6) | 1.00 | 1.00 |
| Stage II/III/IV | 37 (21.8) | 98 (28.4) | 1.555 (1.011-2.391)* | 1.589 (1.029-2.455)* |
| Tumor size | ||||
| <T2 | 133 (73.1) | 233 (67.5) | 1.00 | 1.00 |
| ≧T2 | 49 (26.9) | 112 (32.5) | 1.305 (0.877-1.942) | 1.332 (0.890-1.994) |
| Lymph node metastasis | ||||
| No | 154 (84.6) | 269 (78.0) | 1.00 | 1.00 |
| Yes | 28 (15.4) | 76 (22.0) | 1.554 (0.965-2.502) | 1.583 (0.980-2.559) |
| Distant metastasis | ||||
| No | 166 (91.2) | 312 (90.4) | 1.00 | 1.00 |
| Yes | 16 (8.8) | 33 (9.6) | 1.097 (0.587-2.052) | 1.111 (0.592-2.083) |
Odds ratios with their confidence intervals were estimated by logistic regression models. Ang2, angiopoietin-2; NSCLC, non-small cell lung cancer; OR, odds ratio; CI, confidence interval; AOR, adjusted odds ratio. * p value <0.05 as statistically significant.